Skip to main content

Advertisement

SpringerLink
Log in

Etanercept response in patients with rheumatoid arthritis after secondary loss of efficacy of infliximab

  • Original Article
  • Published:
Modern Rheumatology

Abstract

This study was carried out to determine the effectiveness of half-dose administration of etanercept in patients with rheumatoid arthritis (RA) who exhibited secondary loss of efficacy of infliximab. Seventeen patients were administered 25 mg of etanercept once weekly for at least 1 year after secondary loss of efficacy of infliximab. The mean duration of treatment with infliximab was 32.5 ± 1.3 months. The patient cohort consisted of 3 males and 14 females, with a mean age of 56.3 ± 11.4 years and mean weight of 57.2 ± 10.9 kg. The mean duration of RA was 16.2 ± 10.9 years. The mean Disease Activity Score 28 was decreased significantly, from 5.8 at the initiation of infliximab therapy to 3.6 at the end of observation. There were no withdrawals due to adverse reactions during the study period, although in 2 subjects the agent was changed to tocilizumab due to lack of effect, one after 18 months and the other after 36 months, and 1 subject withdrew after 18 months for financial reasons. A good response can be expected to a half dose of etanercept in patients with secondary loss of efficacy of infliximab. Reduction of the patient’s cost burden also makes this a superior treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Fox DA. Biological therapies: a novel approach to the treatment of autoimmune disease. Am J Med. 1995;99:82–8.

    Article  CAS  PubMed  Google Scholar 

  2. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996;14:397–440.

    Article  CAS  PubMed  Google Scholar 

  3. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alfa. Arthritis Rheum. 1993;36:1681–90.

    Article  CAS  PubMed  Google Scholar 

  4. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet. 2007;370(9602):1861–74.

    Article  CAS  PubMed  Google Scholar 

  5. Matsuno H. Expensive medical expense and cost-reduction strategies in patients with rheumatoid arthritis. Clin Rheumatol Related Res. 2008;39:548–54. (in Japanese; abstract in English).

    Google Scholar 

  6. Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and meta-analysis. J Rheumatol. 2006;33:2398–408.

    CAS  PubMed  Google Scholar 

  7. Van der Heijde DM, van Riel PL, Nuver-Zwart IH, Gribnau FW, van de Putte LB. Effect of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet. 1989;1:1036–8.

    PubMed  Google Scholar 

  8. Fuchs HA, Kaye JJ, Callahan LF, Nance EP, Pincus T. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol. 1989;16:585–91.

    CAS  PubMed  Google Scholar 

  9. O’Dell JR. Treating rheumatoid arthritis; a window of opportunity? Arthritis Rheum. 2002;46:283–5.

    Article  PubMed  Google Scholar 

  10. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum. 2002; 46:328–46.

    Google Scholar 

  11. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Inflixamab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999;354(9194):1932–9.

    Article  CAS  PubMed  Google Scholar 

  12. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med. 1999;130:478–86.

    CAS  PubMed  Google Scholar 

  13. van der Heijde D, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, Melo-Gomes J, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum. 2006;54:1063–74.

    Article  PubMed  CAS  Google Scholar 

  14. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicentre, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26.

    Article  CAS  PubMed  Google Scholar 

  15. van de Putte LB, Rau R, Breedveld FC, Kalden JR, Malaise MG, van Riel PL, et al. Efficacy and safety of the fully human anti-tumor necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis. 2003;62:1168–77.

    Article  PubMed  CAS  Google Scholar 

  16. Gomez-Reino JJ, Carmona L, BIOBADASER group. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther. 2006;8:R29.

    Article  PubMed  CAS  Google Scholar 

  17. Hyrich KI, Lunt M, Watson KD, Symmons DP, Silman AJ. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum. 2007;56:13–20.

    Article  CAS  PubMed  Google Scholar 

  18. Furst DE, Gaylis N, Bray V, Olech E, Yocum D, Ritter J, et al. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. Ann Rheum Dis. 2007;66:893–9.

    Article  CAS  PubMed  Google Scholar 

  19. Berthelot JM, Varin S, Cormier G, Tortellier L, Guillot P, Glemarec J, et al. 25 mg etanercept once weekly in rheumatoid arthritis and spondylarthropathy. Joint Bone Spine. 2007;74:144–7.

    Article  CAS  PubMed  Google Scholar 

  20. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet. 2007;370:1861–74.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest statement

None.

Author information

Authors and Affiliations

  1. Matsuno Clinic for Rheumatic Diseases, 7187-2 Kureha, Toyama, Toyama, 930-0138, Japan

    Hiroaki Matsuno

Authors
  1. Hiroaki Matsuno
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiroaki Matsuno.

About this article

Cite this article

Matsuno, H. Etanercept response in patients with rheumatoid arthritis after secondary loss of efficacy of infliximab. Mod Rheumatol 20, 561–565 (2010). https://doi.org/10.1007/s10165-010-0320-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10165-010-0320-8

Keywords

Search

Navigation